TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B Turnover 31.15%
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
-20.68%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$733M
AUM Growth
-$290M
Cap. Flow
-$4.65M
Cap. Flow %
-0.63%
Top 10 Hldgs %
55.3%
Holding
38
New
–
Increased
2
Reduced
3
Closed
1
Avg Time Held
1.3 years
Top 10 Avg Time Held
0.6 years
Top 20 Avg Time Held
1 year

Top Buys

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$11.8M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$4.63M

Top Sells

Rank Stock Value
1
SLNO icon
Soleno Therapeutics
SLNO
+$13.4M
2
KROS icon
Keros Therapeutics
KROS
+$6.39M
3
IRON icon
Disc Medicine
IRON
+$1.21M
4
RAPT icon
RAPT Therapeutics
RAPT
+$55.4K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CGON icon
1
CG Oncology
CGON
$5.48B
$89.9M 12.26%
3,670,206
– –
2024 Q1
4 quarters
COGT icon
2
Cogent Biosciences
COGT
$4.88B
$41.7M 5.69%
6,964,375
– –
2021 Q4
13 quarters
CNTA
3
DELISTED
Centessa Pharmaceuticals
CNTA
$41.6M 5.67%
2,890,816
– –
2023 Q3
6 quarters
MLYS icon
4
Mineralys Therapeutics
MLYS
$1.84B
$39.2M 5.35%
2,470,265
– –
2024 Q1
4 quarters
OCUL icon
5
Ocular Therapeutix
OCUL
$1.58B
$39M 5.32%
5,319,148
– –
2024 Q1
4 quarters
ABVX icon
6
Abivax
ABVX
$7.68B
$37.9M 5.16%
6,056,596
– –
2023 Q4
5 quarters
SVRA icon
7
Savara
SVRA
$978M
$34.2M 4.67%
12,362,205
– –
2023 Q3
6 quarters
DYN icon
8
Dyne Therapeutics
DYN
$2.81B
$27.7M 3.78%
2,650,150
– –
2023 Q1
8 quarters
DNTH icon
9
Dianthus Therapeutics
DNTH
$4.18B
$27.2M 3.72%
1,501,624
– –
2024 Q4
1 quarter
TYRA icon
10
Tyra Biosciences
TYRA
$1.29B
$27M 3.68%
2,898,103
+909,000
+46% +$11.8M
2021 Q4
13 quarters
XNCR icon
11
Xencor
XNCR
$1.74B
$26.1M 3.56%
2,452,138
– –
2024 Q3
2 quarters
IRON icon
12
Disc Medicine
IRON
$2.14B
$23.1M 3.15%
465,257
-21,700
-4% -$1.21M
2024 Q2
3 quarters
TRML icon
13
DELISTED
Tourmaline Bio
TRML
$22.5M 3.07%
1,477,593
– –
2023 Q4
5 quarters
CDTX icon
14
DELISTED
Cidara Therapeutics
CDTX
$21.7M 2.96%
1,005,901
– –
2024 Q4
1 quarter
AMLX icon
15
Amylyx Pharmaceuticals
AMLX
$3.39B
$21M 2.87%
5,943,812
+1,300,000
+28% +$4.63M
2024 Q3
2 quarters
SLNO icon
16
DELISTED
Soleno Therapeutics
SLNO
$19.6M 2.68%
275,000
-275,000
-50% -$13.4M
2024 Q1
4 quarters
EYPT icon
17
EyePoint Inc
EYPT
$259M
$19.4M 2.64%
3,572,335
– –
2024 Q2
3 quarters
GPCR icon
18
Structure Therapeutics
GPCR
$1.56B
$18.4M 2.51%
1,063,000
– –
2023 Q1
8 quarters
UPB icon
19
Upstream Bio Inc
UPB
$187M
$17.1M 2.34%
2,801,763
– –
2024 Q4
1 quarter
RAPT icon
20
DELISTED
RAPT Therapeutics
RAPT
$16M 2.18%
1,636,275
-5,633
-0.3% -$55.4K
2024 Q4
1 quarter
FULC icon
21
Fulcrum Therapeutics
FULC
$280M
$15.1M 2.06%
5,250,000
– –
2024 Q3
2 quarters
ATXS icon
22
DELISTED
Astria Therapeutics
ATXS
$14.7M 2.01%
2,761,861
– –
2024 Q1
4 quarters
TNGX icon
23
Tango Therapeutics
TNGX
$3.74B
$14.7M 2.01%
10,736,000
– –
2024 Q4
1 quarter
CMPS icon
24
Compass Pathways
CMPS
$1.56B
$11M 1.51%
3,858,000
– –
2023 Q3
6 quarters
KURA icon
25
Kura Oncology
KURA
$855M
$9.4M 1.28%
1,423,642
– –
2022 Q1
12 quarters
1
2

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return
CCMIC
Cardinal Capital Management Inc (Canada) Winnipeg, Manitoba, Canada $4.13B AUM 31.23% 1-Year Est. Return

TCG Crossover Management's Q1 2025 Portfolio in Review

As of Q1 2025, TCG Crossover Management held 38 positions worth $733M, down 28% from $1.02B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Trading was light in Q1 2025: portfolio turnover was 2.6%. TCG Crossover Management opened no new positions and exited 1, leaving the 38-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TCG Crossover Management added most to Tyra Biosciences in Q1 2025, an estimated $11.8M increase.
  • TCG Crossover Management's biggest Q1 2025 reduction was Soleno Therapeutics, cutting an estimated $13.4M.
  • TCG Crossover Management fully exited Keros Therapeutics in Q1 2025, selling an estimated $6.39M.
  • TCG Crossover Management's ten largest holdings make up 55% of its $733M portfolio in Q1 2025.
  • TCG Crossover Management opened 0 new positions and closed 1 in Q1 2025.
  • TCG Crossover Management's portfolio value fell 28% quarter-over-quarter to $733M.

Based on TCG Crossover Management's 13F filing for Q1 2025, filed 14 May 2025.